WHO WE ARE

We have sat where your investors sit.

Working in English and French, from Geneva.

Patricia Delaite, MD

THE PHYSICIAN SCIENTIST

Patricia Delaite, MD

MD, trained in internal medicine and oncology, with a focus on geroscience

Patricia Delaite is a physician scientist with two decades in drug development. She trained in internal medicine and oncology at the University Hospital of Geneva and practised there for ten years before moving to industry.

At Eli Lilly, Novartis, ARIAD and Incyte she worked from first-in-human studies to registration. At Incyte she led two programmes in graft-versus-host disease, with three pivotal trials that led to full approval, and dealt directly with the FDA, EMA and PMDA.

She was then twice a biotech Chief Medical Officer. At AMAL Therapeutics she took a first-in-class vaccine into the clinic with approval from two health authorities, and the design of that study contributed to the company's exit. At Nouscom she built the clinical function from the ground up, and early Phase II data from her programme supported a Series B tranche and the Series C.

She sat on the board of Cantargia, listed on Nasdaq Stockholm, and chaired the board of TheraPPI Biosciences through its pre-seed round. She co-directed a module of the University of Geneva's master's programme in drug discovery and clinical development. She co-founded LSI in 2022. With Jean-Marc Suter she has advised around ten biotech, medtech and digital health companies on strategy and value creation, and she leads the review of the science, the clinical plan and the regulatory path. She also acts as fractional CMO and writes LSI's reviews, the first of which is the Longevity Review.

Selected experience

  • 2022 to today · Life Sciences Intelligentia, co-founder, board member and Scientific Investment Manager
  • 2023 to 2025 · TheraPPI Biosciences, Chair of the Board
  • 2017 to 2023 · Cantargia (Nasdaq Stockholm), Independent board member
  • 2020 to 2022 · Nouscom, Chief Medical Officer
  • 2018 to 2019 · AMAL Therapeutics, Chief Medical Officer
  • 2015 to 2017 · Incyte, Executive Medical Director, Clinical Development
  • Earlier · ARIAD, Novartis, Eli Lilly; University Hospital of Geneva

Education

  • 2021 · PME Board Academy certificate, Startup Board Academy
  • 2009 · EMBA in Management of Technology, EPFL and HEC Lausanne
  • 1991 · Diploma of Medicine, University of Geneva

Languages

French, English

LinkedIn
Jean-Marc Suter

THE BANKER

Jean-Marc Suter

Swiss banker in Geneva, London and Abu Dhabi

Jean-Marc Suter is a Swiss banker with more than thirty years in Geneva, London and Abu Dhabi. He started at Credit Suisse in Geneva, then moved to Crédit Agricole in London as head of the international department and deputy head of private banking, with a team of 45, where he obtained a UK banking licence.

From 2004 he worked in Abu Dhabi, as director at the representative offices of Credit Suisse and UBS, executive director at Julius Baer, and managing director of Gonet & Cie, whose office and banking licence he set up. For fourteen years, in parallel, he presided over the Swiss Business Council Abu Dhabi, which he took from bankruptcy to stable finances and made a partner of the Swiss authorities.

He co-founded LSI in 2022 with Patricia Delaite and is its Managing Director. He built its data-room and due-diligence method and, with her, has advised around ten biotech, medtech and digital health companies on strategy and value creation. At LSI he runs the financials, the corporate file and the data room, and is the fractional CFO.

Selected experience

  • 2022 to today · Life Sciences Intelligentia, co-founder and Managing Director
  • 2005 to 2019 · Swiss Business Council Abu Dhabi, President
  • 2013 to 2017 · Gonet & Cie, Abu Dhabi, Managing Director
  • 2009 to 2011 · Julius Baer, Abu Dhabi, Executive Director
  • 2004 to 2008 · Credit Suisse, then UBS, Abu Dhabi, Director
  • 2000 to 2004 · Crédit Agricole, London and Geneva, Senior Vice President
  • 1991 to 2000 · Credit Suisse, Geneva, Vice President

Education

  • 2022 · Alternative Investments certificate, Harvard Business School Online
  • 2021 · Disruptive Strategy certificate, Harvard Business School Online
  • 2021 · PME Board Academy certificate, Startup Board Academy
  • 2021 · Technology Entrepreneurship: Lab to Market, HarvardX
  • 1990 · Licence in Commercial and Industrial Sciences, business management, University of Geneva

Languages

French, English

LinkedIn